PURPOSE: To introduce an application of area-under-the-curve (AUC) that can enrich interpretation of response analysis and illustrate this method on sleep quality scores in patients with fibromyalgia. METHODS: Data were from a 14-week, randomized trial conducted in 750 patients with fibromyalgia treated withplacebo or pregabalin (300, 450, or 600 mg/day); sleep quality was assessed daily by the patient using an 11-point numeric rating scale. RESULTS: Response profiles were implemented for responders who improved (or stayed the same) numerically in sleep quality scores from baseline to week 14 and, separately, for non-responders who worsened (numerically less favorable scores at week 14). Differences between pregabalin and placebo were assessed using an AUC analysis. Improvement in sleep quality was significantly better with pregabalin and can be interpreted as if pregabalin responders improved by 10.8% (300 mg), 14.7% (450 mg), and 19.0% (600 mg) above the placebo responders. Conversely, decrement in sleep quality was worse with placebo and can be interpreted as if placebo non-responders worsened by 3.6% (300 mg), 2.9% (450 mg), and 3.9% (600 mg) over pregabalin non-responders. CONCLUSIONS: The application of an AUC analysis to response profiles for responders and non-responders can enrich the interpretation of sleep quality scores in patients with fibromyalgia. The method can be applied more generally to facilitate and enhance the interpretation of treatment differences on outcomes.
RCT Entities:
PURPOSE: To introduce an application of area-under-the-curve (AUC) that can enrich interpretation of response analysis and illustrate this method on sleep quality scores in patients with fibromyalgia. METHODS: Data were from a 14-week, randomized trial conducted in 750 patients with fibromyalgia treated with placebo or pregabalin (300, 450, or 600 mg/day); sleep quality was assessed daily by the patient using an 11-point numeric rating scale. RESULTS: Response profiles were implemented for responders who improved (or stayed the same) numerically in sleep quality scores from baseline to week 14 and, separately, for non-responders who worsened (numerically less favorable scores at week 14). Differences between pregabalin and placebo were assessed using an AUC analysis. Improvement in sleep quality was significantly better with pregabalin and can be interpreted as if pregabalin responders improved by 10.8% (300 mg), 14.7% (450 mg), and 19.0% (600 mg) above the placebo responders. Conversely, decrement in sleep quality was worse with placebo and can be interpreted as if placebo non-responders worsened by 3.6% (300 mg), 2.9% (450 mg), and 3.9% (600 mg) over pregabalin non-responders. CONCLUSIONS: The application of an AUC analysis to response profiles for responders and non-responders can enrich the interpretation of sleep quality scores in patients with fibromyalgia. The method can be applied more generally to facilitate and enhance the interpretation of treatment differences on outcomes.
Authors: Philip Raskin; Leslie Klaff; Janet McGill; Stephen A South; Priscilla Hollander; Naum Khutoryansky; Paula M Hale Journal: Diabetes Care Date: 2003-07 Impact factor: 19.112
Authors: Phillip J Mease; Lesley M Arnold; Leslie J Crofford; David A Williams; I Jon Russell; Louise Humphrey; Linda Abetz; Susan A Martin Journal: Arthritis Rheum Date: 2008-07-15
Authors: Lesley M Arnold; I Jon Russell; E W Diri; W Rachel Duan; James P Young; Uma Sharma; Susan A Martin; Jeannette A Barrett; George Haig Journal: J Pain Date: 2008-06-03 Impact factor: 5.820